别名 pim-3 oncogene、Pim-3 proto-oncogene, serine/threonine kinase、PIM3 + [1] |
简介 Proto-oncogene with serine/threonine kinase activity that can prevent apoptosis, promote cell survival and protein translation. May contribute to tumorigenesis through: the delivery of survival signaling through phosphorylation of BAD which induces release of the anti-apoptotic protein Bcl-X(L), the regulation of cell cycle progression, protein synthesis and by regulation of MYC transcriptional activity. Additionally to this role on tumorigenesis, can also negatively regulate insulin secretion by inhibiting the activation of MAPK1/3 (ERK1/2), through SOCS6. Involved also in the control of energy metabolism and regulation of AMPK activity in modulating MYC and PPARGC1A protein levels and cell growth. |
作用机制 PIM1抑制剂 [+2] |
在研适应症 |
最高研发阶段临床2期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
作用机制 CDK4抑制剂 [+2] |
在研机构 |
原研机构 |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
作用机制 PIM1抑制剂 [+2] |
在研适应症- |
非在研适应症 |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期1800-01-20 |
开始日期2023-05-22 |
开始日期2022-11-04 |
申办/合作机构 |
开始日期2022-10-27 |
申办/合作机构 |